Why lot-specific testing matters

Solid-phase peptide synthesis builds a chain one residue at a time. Each residue requires a coupling reaction, and each coupling is imperfect — a small fraction of chains fail to react and become deletion sequences. Those failures are not corrected later; they persist into the crude product and have to be removed by purification.

Because the steps are sequential, the yields multiply. For a peptide of n residues there are n − 1 couplings, so the theoretical maximum fraction of full-length chains is the per-step efficiency raised to that power.

Crude full-length yield for a 15-residue peptide — fourteen sequential couplings, theoretical maximum before purification. At 95.8% per step it falls to 54.4%.

Between 99.5% and 98% per step — a difference no operator would notice in the moment — the crude product goes from nine parts in ten being correct to three parts in four. Longer sequences amplify this further, which is why a 30-mer is a materially harder synthesis than a 15-mer rather than merely twice the work.

Coupling efficiency is not a constant of the molecule. It is an outcome of conditions, and every one of these moves between runs:

The last two are worth emphasising because they affect the numbers on the certificate without touching the chemistry of the peptide at all. Two batches of identical sequence and identical chromatographic purity can differ measurably in how much peptide a vial contains.

A common practice in this market is to publish one certificate per product. It sits on the product page, it is real, it was produced by a real laboratory — and it describes a batch that may have been made a year ago and sold out long since.

This is not necessarily dishonest. It is often presented as illustrative. But it answers a question nobody asked: buyers want to know about the material they are receiving, and a representative certificate cannot speak to that. Given the batch-to-batch variability above, it is closer to a specification than to a result.

The phrase gets used loosely. Meaningfully, it requires all of:

• A lot number on the certificate that matches the physical vial.
• A test date after the manufacture date. Testing that predates the batch is testing of something else.
• A named laboratory, so the result is attributable.
• Testing of that lot, not of a reference batch of the same sequence.
• A durable published record, so the certificate remains retrievable after the lot sells out — and can be compared against the next one.

The last point is the one most often missing, and it is what turns lot testing from a claim into something checkable. A supplier that publishes every lot builds a record that can be audited over time. A supplier that publishes only the current lot can quietly replace an inconvenient result.

A lot is only a meaningful unit if the material in it is uniform. Lyophilised peptide is a fine powder that is filled into vials, and if the bulk was not properly blended before filling, vials from different points in the fill can differ — particularly in moisture content, which varies with position in the lyophiliser.

This is a limit on what any lot-level certificate can promise. It is small relative to batch-to-batch variation, but it is the reason a certificate describes a lot rather than a vial, and the reason careful work re-checks concentration rather than assuming the certificate transfers exactly to the vial in hand.

We test by lot and publish each certificate at its own address, including lots that have sold out — they are in the certificate library, and each is reachable from the QR code on its vial. Where testing is pending, the product says so and names the specification it was purchased against, rather than displaying a certificate from an earlier batch.

The intent is that the record is checkable in both directions — you can verify the material you received, and you can see whether our results have been consistent across batches. A supplier's second certificate is more informative than its first.

Why can't a supplier just test one batch and publish that?

Because peptide synthesis is sensitive to conditions that change between runs. A single-point change in coupling efficiency shifts crude purity by double digits on a 15-mer, and purification decisions, residual moisture and counterion load all vary independently on top of that. The tested batch is evidence about the tested batch.

How do I check whether a certificate applies to my vial?

Compare the lot number on the certificate to the one on the vial label. They must match exactly. Then check that the analysis date falls after the manufacture date. If either check fails, the certificate is describing different material.

Do longer peptides have lower purity?

All else equal, yes — and the relationship is exponential rather than linear, because coupling yields multiply across steps. This is why longer sequences generally carry lower purity specifications, need more aggressive purification, and cost more per milligram. It is a property of the chemistry, not a sign of a careless supplier.

Can two lots with the same purity have different peptide content?

Yes, and it is common. Purity describes the peptide fraction; content describes how much of the vial is peptide. Residual moisture from the lyophilisation cycle and counterion load from final purification both vary between batches and both shift content without affecting chromatographic purity at all — see HPLC purity vs net peptide content.

• Standard references on solid-phase peptide synthesis, for stepwise coupling efficiency and the origin of deletion sequences.
• United States Pharmacopeia, general chapter <1052>, Biotechnology-Derived Articles — Amino Acid Analysis, for content determination methodology.
• Manufacturer technical documentation on lyophilisation cycle effects on residual moisture and gross weight.